Factors affecting stability of plasma brain-derived neurotrophic factor

Wessels, Jocelyn M.; Agarwal, R. K.; Somani, Aamer; Agarwal, Sanjay; Foster, Warren G.

doi:10.1038/s41598-020-77046-6

Cited by 10 publications

(7 citation statements)

References 43 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Although our study validates altered expression in the depressed patient, we also discovered a significant amount of heterogeneity between studies, significantly influencing the BDNF expression in drug‐naïve or drug‐free depressed patients. We speculate that a high heterogeneity might have resulted from between‐sample characteristics, such as alcohol consumption and cigarette smoking, sleep‐related issue, circadian variation, socioeconomic status, and differences in the severity of patient samples’ clinical features such as a history of depression (Bus et al., 2012 ; Miranda et al., 2019 ; Wessels et al., 2020 ). These heterogeneous variables are interdependent in a complex manner, and any disruption of this complex mechanism may give rise to depression (Athira et al., 2020 ; Beirão et al., 2020 ; McEwen & Akil, 2020 ).…”

Section: Discussionmentioning

confidence: 99%

Association of peripheral manifestation of brain‐derived neurotrophic factor with depression: A meta‐analysis

Tiwari

Wong

et al. 2022

Brain and Behavior

View full text Add to dashboard Cite

Background:The relationship between brain-derived neurotrophic factor (BDNF) and depression is a hot topic in research as several results of preclinical and clinical studies have shown controversial results. Our meta-analysis aims to evaluate and update the current status of peripheral BDNF with depression. Methods:We performed a meta-analysis by comprehensively searching PubMed and Web of Science for English-language literature from inception to 1st of June 2020. The search terms included brain-derived neurotrophic factor or BDNF in combination with depression, without year restriction. Using STATA software, data were pooled using a random-effects model. Results:In our literature search, 24 studies involving 1130 depressed patients and 1378 healthy individuals met our inclusion criteria. The results of our meta-analysis showed that the peripheral levels of BDNF levels significantly decreased in depression than nondepressed healthy controls (SMD = −0.89, 95% CI = −1.41, −0.38, p < .0001); however, the significant heterogeneity among studies (Q = 740.91, I 2 = 96.8; p < .001) was discovered. Trim-and-fill estimations for the adjustment of publication bias indicated that publication bias had no impact on our results. Our sub-group analysis showed that a history of depression and alcohol consumption had an effect on the level of BDNF. In addition, age and gender did not affect the heterogeneity of BDNF in the meta-analysis. Conclusions:Although decreased peripheral expression of BDNF certainly presents a risk of depression, we cannot find a definite relationship between the peripheral level of BDNF with depression to use BDNF as a reliable biomarker to assess the depression in clinical practice. We propose that future research should consider all the factors affecting BDNF and assess the level of proBDNF and mBDNF separately while evaluating the patients with depression objectively.

show abstract

Section: Discussionmentioning

confidence: 99%

Association of peripheral manifestation of brain‐derived neurotrophic factor with depression: A meta‐analysis

Tiwari

Wong

et al. 2022

Brain and Behavior

View full text Add to dashboard Cite

show abstract

“…BDNF concentrations in plasma are much lower than in serum, while serum BDNF is more stable, its amount is modified by temperature and time of clotting [ 36 ] Plasma BDNF is influenced by several clinical factors, such as, inter alia, body weight [ 37 ] and circadian rhythm [ 35 ] and is sensitive to preparation procedure [ 38 – 40 ]. We can only speculate that AF-BDNF acts like human plasma BDNF and we did not find differences between group A and group B apart from maternal pre-pregnancy BMI.…”

Section: Discussionmentioning

confidence: 99%

High maternal BMI and low maternal blood BDNF may determine the limit of detection of amniotic fluid BDNF throughout gestation: Analysis of mother-fetus trios and literature review

et al. 2022

View full text Add to dashboard Cite

Objective An increasing number of studies show the importance of brain-derived neurotrophic factor (BDNF) acting at the feto-placental interface, however, only a few studies describe BDNF levels in amniotic fluid (AF). Methods In this cross-sectional, prospective study, 109 maternal blood-amniotic fluid pairs (including 66 maternal blood-fetal-blood-amniotic fluid trios) were analyzed. BDNF concentrations were measured with a commercially available immunoassay. Results In 71 AF from 109 samples, AF-BDNF concentrations were below the lowest limit of Quantitation (LLoQ) of 1.19 pg/ml (group A), leaving 38 samples with measurable BDNF concentrations (group B). Patients in group A showed significantly higher maternal BMI before pregnancy (mean±SD 26.3± 6.7 (kg/m2) vs. 23.8 ±4.5 (kg/m2) p = 0.04) and lower maternal blood BDNF concentrations than the other group (mean±SD 510.6 ± 554.7 pg/ml vs. mean±SD 910.1± 690.1 pg/ml; p<0.0001). Spearman correlation showed a negative correlation between maternal BMI before pregnancy and maternal BDNF concentrations (r = -0.25, p = 0.01). Conclusion Our study is the first to correlate AF-BDNF samples with the corresponding maternal and fetal blood-BDNF samples. The significant negative correlation between maternal BMI before pregnancy and maternal BDNF and AF-BDNF concentrations below the limit of detection has to be evaluated in further studies.

show abstract

“…(2014), where BDNF measured in serum increased during the first hour of coagulation at 25°C and were relatively stable with a clotting time between one and 48 h. In contrast, a study by Amadio and colleagues (2017), demonstrated that serum BDNF samples incubated at 37°C, reached a plateau after 30 min, whereas 120 min were necessary to obtain similar BDNF levels at room temperature. Furthermore, Wessels and colleagues (2020) noted that the type of plasma separator tube, storage duration, and number of freeze–thaw cycles can impact the quantification of plasma BDNF concentration. In addition, plasma stored at −80°C compared to −20°C tends to have less variability in mean BDNF concentrations.…”

Section: Measurement Of Bdnfmentioning

confidence: 99%

BDNF as a biomarker for neuropathic pain: Consideration of mechanisms of action and associated measurement challenges

Thakkar

Acevedo

2023

Brain and Behavior

View full text Add to dashboard Cite

Introduction:The primary objective of this paper is to (1) provide a summary of human studies that have used brain derived neurotrophic factor (BDNF) as a biomarker, (2) review animal studies that help to elucidate the mechanistic involvement of BDNF in the development and maintenance of neuropathic pain (NP), and (3) provide a critique of the existing measurement techniques to highlight the limitations of the methods utilized to quantify BDNF in different biofluids in the blood (i.e., serum and plasma) with the intention of presenting a case for the most reliable and valid technique. Lastly, this review also explores potential moderators that can influence the measurement of BDNF and provides recommendations to standardize its quantification to reduce the inconsistencies across studies. Methods:In this manuscript we examined the literature on BDNF, focusing on its role as a biomarker, its mechanism of action in NP, and critically analyzed its measurement in serum and plasma to identify factors that contribute to the discrepancy in results between plasma and serum BDNF values.Results: A large heterogenous literature was reviewed that detailed BDNF's utility as a potential biomarker in healthy volunteers, patients with chronic pain, and patients with neuropsychiatric disorders but demonstrated inconsistent findings. The literature provides insight into the mechanism of action of BDNF at different levels of the central nervous system using animal studies. We identified multiple factors that influence the measurement of BDNF in serum and plasma and based on current evidence, we recommend assessing serum BDNF levels to quantify peripheral BDNF as they are more stable and sensitive to changes than plasma BDNF. Conclusion:Although mechanistic studies clearly explain the role of BDNF, results from human studies are inconsistent. More studies are needed to evaluate the methodological challenges in using serum BDNF as a biomarker in NP.

show abstract

Factors affecting stability of plasma brain-derived neurotrophic factor

Cited by 10 publications

References 43 publications

Association of peripheral manifestation of brain‐derived neurotrophic factor with depression: A meta‐analysis

Association of peripheral manifestation of brain‐derived neurotrophic factor with depression: A meta‐analysis

High maternal BMI and low maternal blood BDNF may determine the limit of detection of amniotic fluid BDNF throughout gestation: Analysis of mother-fetus trios and literature review

BDNF as a biomarker for neuropathic pain: Consideration of mechanisms of action and associated measurement challenges

Contact Info

Product

Resources

About